Table 5.
PD-L1 expression in NSCLC according to gender, common driver mutation status, smoking status and histological subtype (N = 191)
| Characteristic | No. of patients (%) | P value* | ||
|---|---|---|---|---|
| PD-L1 expression |
TPS < 1% (No expression) |
TPS 1% to 49% (Low expression) |
TPS ≥ 50% (High expression) |
|
| Gender | ||||
| Male (n = 115) | 40 (34.8%) | 47 (40.9%) | 28 (24.3%) | 0.087 |
| Female (n = 76) | 32 (42.1%) | 34 (44.7%) | 10 (13.2%) | |
| EGFR mutation | ||||
| Present | 33 (40.7%) | 42 (51.9%) | 6 (7.4%) | < 0.0001 |
| Absent | 39 (35.5%) | 39 (35.5%) | 32 (29.1%) | |
| ALK | ||||
| Present (n = 8) | 1 (12.5%) | 6 (75.0%) | 1 (12.5%) | 1.000 |
| Absent (n = 183) | 71 (38.8%) | 75 (41.0%) | 37 (20.2%) | |
| Smoking status | ||||
| Never smoker (n = 101) | 41 (40.6%) | 46 (45.5%) | 14 (13.9%) | 0.042 |
| Ever smoker (n = 90) | 31 (34.4%) | 35 (38.9%) | 24 (26.7%) | |
| Pack-years of smoking among ever smokers (n = 90) | ||||
| < 20 (Light smoker n = 16) | 8 (50.0%) | 7 (43.8%) | 1 (6.3%) | 0.034 |
| 20–39 (Moderate smoker n = 21) | 6 (28.6%) | 11 (52.4%) | 4 (19.0%) | |
| ≥ 40 (Heavy smoker n = 53) | 17 (32.1%) | 17 (32.1%) | 19 (35.8%) | |
| Ever smoker (n = 90) | ||||
| Current smoker (n = 53) | 20 (37.7%) | 17 (32.1%) | 16 (30.2%) | 0.508 |
| Former smoker (n = 37) | 11 (29.7%) | 18 (48.6%) | 8 (21.6%) | |
| Histological subtype of NSCLC | ||||
| Squamous cell (n = 34) | 12 (35.3%) | 15 (44.1%) | 7 (20.6%) | 1.000 |
| Adenocarcinoma (n = 147) | 57 (38.8%) | 61 (41.5%) | 29 (19.7%) | |
TPS = Tumor proportion score
*In each group, comparison is between high PD-L1 expression (TPS ≥ 50%) versus no (TPS < 1%) and low PD-L1 expression (TPS 1%-49%)